Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01135316 · ClinicalTrials.gov registry record
Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR
A clinical trial, sponsored by Lantheus Medical Imaging.
- Completed
- Registry status
- 2
- Enrollment target
NCT01135316 is a clinical trial that has completed, run by Lantheus Medical Imaging. The registered enrollment target is 2 participants.
The verdict
NCT01135316 has completed, sponsored by Lantheus Medical Imaging.
- COMPLETED
- Registry status
- 2 participants
- Enrollment target
Study Summary
Phase 4, open-label, two-year, prospective, multi-center, follow-up study conducted at up 15 sites in USA. Approximately 1,000 patients with moderate-to-severe CKD will be enrolled and followed for up to 24 months.
Interventions
- DRUG Ablavar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2009-10 |
| Est. Completion | 2013-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01135316
The ClinicalTrials.gov registry entry for NCT01135316 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lantheus Medical Imaging, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ablavar is the first listed.
NCT01135316 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01135316 about?
NCT01135316 is a clinical study titled "Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR". Phase 4, open-label, two-year, prospective, multi-center, follow-up study conducted at up 15 sites in USA. Approximately 1,000 patients with moderate-to-severe CKD will be enrolled and followed for up to 24 months.
What is the current status of trial NCT01135316?
This trial is currently completed. The enrollment target is 2 participants. The study started on 2009-10. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01135316?
The interventions under investigation include: Ablavar (DRUG).
Who is sponsoring clinical trial NCT01135316?
This trial is sponsored by Lantheus Medical Imaging, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.